latest update:
[TrialBase DB]

trial summary · NCT07743190

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

NeoTILs: A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Triple Negative Breast Cancer (TNBC), sponsored by Medical University of South Carolina. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07743190phase PHASE2enrollment 55start 2027-01-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This study tests a new treatment approach for people with early-stage triple negative breast cancer whose tumors have a high number of immune cells, called tumor-infiltrating lymphocytes or TILs, as seen by a pathologist on tissue review. A high TIL count is a sign the cancer may respond especially well to chemotherapy and immunotherapy together, meaning more toxic treatment may not be needed for everyone. All patients with high TILs will receive 12 weeks of chemotherapy (carboplatin and paclitaxel) with the immunotherapy drug pembrolizumab before surgery, without anthracyclines, a class of chemotherapy drugs that is effective but carries risks of heart damage and, rarely, bone marrow disorders or leukemia. Patients with no cancer found at surgery continue on pembrolizumab alone. Those with residual cancer receive anthracycline-based chemotherapy plus pembrolizumab, closer to current standard treatment. The goal is to personalize treatment, sparing anthracyclines for patients likely to do well without them while reserving stronger therapy for those who need it. The main measure of success is the pathologic complete response rate, with cancer-free survival and overall survival also assessed.

Source record: https://clinicaltrials.gov/study/NCT07743190

Facts

registry idNCT07743190
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionTriple Negative Breast Cancer (TNBC)
sponsorMedical University of South Carolina
sponsor classOTHER
enrollment55
start date2027-01-01
primary completion2029-09-22
completion2034-05-29
results postednot reported

Conditions

  • Triple Negative Breast Cancer (TNBC)
  • Elevated Tumor-Infiltrating Lymphocytes

Interventions

  • Carboplatin
  • Paclitaxcel
  • Pembrolizumab

Countries

  • United States

Intervention types: DRUG

Work with this record